Gut microbiome modulation by Bacillus coagulans BCP92 in healthy subjects: randomized double-blind placebo-controlled clinical trial
B. coagulans BCP92 supplementation for 42 days did not produce major changes in gut microbiota composition in healthy individuals, with only subtle shifts detected.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
Metagenomic analysis showed no major alterations in gut microbiome composition following supplementation with 1 billion CFU/capsule for 42 days. Only subtle changes in some taxa and a slight increase in fecal short-chain fatty acids (SCFAs) were reported. The authors' conclusion uses stronger language than the results section warrants.
How it was done
Double-blind RCT with 48 healthy participants assigned to B. coagulans BCP92 (1 billion CFU/capsule) or maltodextrin placebo for 42 days, followed by microbiome composition and SCFA analyses.
Risk of bias
Small sample size (n=48) and enrollment of healthy individuals — a population with potentially more resilient microbiota — limit generalizability. The abstract lacks statistical detail, effect sizes, and baseline group comparisons.
What this study does NOT prove
This study does not prove that B. coagulans BCP92 produces clinically meaningful benefits on the gut microbiota of healthy individuals.
In clinical practice
Available data do not support clinical use of B. coagulans BCP92 for microbiota modulation in healthy subjects. Subtle changes without clear clinical significance have limited practical value.
Limitations
Small sample size (n=48) and enrollment of healthy individuals — a population with potentially more resilient microbiota — limit generalizability. The abstract lacks statistical detail, effect sizes, and baseline group comparisons.
Technical appendix
Version history
- 1.0 · 2026-09-02 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.